FDA record research

Closed Antineoplastic And Hazardous Drug Reconstitution And Transfer System (ONB) — FDA decisions, comparisons and evidence

The 2021–2025 analysis contains 21 selected substantially-equivalent FDA decisions under primary product code ONB. Use it to compare documented submissions and evidence with your product. A separate 2026 update contains 0 decisions through 2026-09-27. The latest selected decision across the acquired endpoint is dated 2025-12-05. Neither set establishes a suitable predicate or the route for your device. The complete-year window has 21 decisions; the separate all-observed-date count is 41. These denominators describe different date ranges.

Evidence retrieved 2026-10-07. Source versions and topic-specific limits are listed below.

Recorded scope and its declared regulatory reference

An exact FDA-record regulation_number match to one acquired Title 21 section. Records with the same normalized scope definition, class, regulation and recorded submission/GMP flags are grouped. Sparse definitions and generic exemption boilerplate do not qualify. No text-similarity equivalence or legal applicability is inferred.

What scope does the FDA record describe?

Reconstitute and transfer antineoplastic and other hazardous drugs in healthcare setting indicated to reduce exposure of healthcare personnel to chemotherapy agents in healthcare setting.

Compare the proposed indication, user, anatomy, technology and operating principle with this actual scope; record differences and unresolved facts.

Cited source

Which current section does the record cite?

§ 880.5440 Intravascular administration set. (a) Identification. An intravascular administration set is a device used to administer fluids from a container to a patient's vascular system through a needle or catheter inserted into a vein. The device may include the needle or catheter, tubing, a flow regulator, a drip chamber, an infusion line filter, an I.V. set stopcock, fluid delivery tubing, connectors between parts of the set, a side tube with a cap to serve as an injection site, and a hollow spike to penetrate and connect the tubing to an I.V. bag or other infusion fluid container. (b) Classification. Class II (special controls). The special control for pharmacy compounding systems within this classification is the FDA guidance document entitled “Class II Special Controls Guidance Document: Pharmacy Compounding Systems; Final Guidance for Industry and FDA Reviewers.” Pharmacy compounding systems classified within the intravascular administration set are exempt from the premarket notification procedures in subpart E of this part and subject to the limitations in § 880.9. [45 FR 69682, Oct. 21, 1980, as amended at 66 FR 15798, Mar. 21, 2001]

Read the identification, classification, conditions and referenced limitations in the cited section. A numeric reference match is not a buyer classification or exemption determination.

Cited source

Historical FDA comparison

2021–2025: five complete calendar years

Primary code ONB

All statistics in this section use decisions dated 2021-01-01 to 2025-12-31. The partial 2026 update below is excluded from these distributions.

21Selected decisions in these five years

115.0Median receipt-to-decision calendar days

21Valid date pairs in the distribution

The middle 50% of the 21 valid date pairs spans 67.0–268.0 calendar days. This describes selected recorded submissions, including elapsed time outside active FDA review. It is not an FDA review-time measure or a delivery promise.

20213

20221

20233

20248

20256

Compare like submission types

Recorded type	Decisions	Valid date pairs	Median calendar days	Middle 50%
Special	8	8	Withheld: n < 20	—
Traditional	13	13	Withheld: n < 20	—

Different submission types and evidence packages are not interchangeable. These selected records do not establish that a particular route is available for your product.

Statistical source: FDA openFDA 510(k) decision dataset. Partition 1 Download the identified records and dates (CSV).

Filters, exclusions and reproducible calculation

Deduplicate by official submission ID across the complete current manifest partitions. Select exact primary product code, K-number format and the stated SE decision codes with valid dates. Recent distributions use the five complete calendar years preceding the latest valid endpoint decision year. Partial-year counts compare equal January-to-cutoff periods. Quartiles use linear interpolation at (n-1)*p and are withheld below 20 valid date pairs. The analysis n describes only its declared complete-year window; selected_se_n separately counts all selected recorded dates through the cutoff.

41 selected records across all observed dates; 0 other/invalid identifier or decision-date records excluded. 0 missing or invalid date pairs in the five-year window.

Date fields: date_received → decision_date. Quantiles: Hyndman–Fan type 7: linear interpolation at (n − 1) × p; displayed to one decimal; n ≥ 20 valid pairs.

Receipt-to-decision calendar elapsed time includes time outside active FDA review; it is not FDA review time, a promised project timeline or an estimate of future clearance. This selected recorded cohort does not include all applications or establish a success probability, predicate suitability, market size, current market availability or legal authorization for another product.

Calculation fda-buyer-research-3 · database cutoff 2026-09-27. CSV rows identify each official K-number, cohort, date pair, exclusion reason and source version.

Separate partial-year update

2026 decisions through 2026-09-27

0 selected decisions from 2026-01-01 to 2026-09-27. The equivalent previous-year period contains 4 decisions through 2025-09-27. These counts describe the records; they are not market growth or submission success rates.

Named records to investigate

Latest decisions across the database

These dated records may come from 2026 or earlier years. They are a separate investigation list, not the five-year statistical cohort. Compare the actual indications and technology before considering a record as a comparator.

Official record / device	Recorded applicant	Decision	Recorded type	Calendar days
K251722 ↗ProSeal Transfer Injector (421120, 421130, 421140)	Epic Medical Pte. , Ltd.	2025-12-05	Special	184
K253033 ↗Chemfort® 28-day 20 mm Vial Adaptor and 13 mm Convertor	Simplivia Healthcare , Ltd.	2025-10-21	Special	29
K250059 ↗BD PhaSeal Optima Connecting Set (C83-O); BD PhaSeal Optima Spike Set (C180-O)	Becton, Dickinson and Company	2025-09-12	Traditional	245
K251411 ↗Chemfort Female Luer Lock Adaptor	Simplivia Healthcare , Ltd.	2025-08-05	Traditional	90
K251340 ↗ProSeal Bag Spike with Additive Port (423370ST, 423370)	Epic Medical Pte. , Ltd.	2025-05-29	Special	29
K243976 ↗ZeroClear Bag Access (423100)	Epic Medical Pte. , Ltd.	2025-01-22	Special	30
K240517 ↗ProSeal Vented Universal Vial Adaptor	Epic Medical Pte. , Ltd.	2024-12-26	Traditional	307
K241988 ↗ProSeal Closed System Bag Access	Epic Medical Pte. , Ltd.	2024-10-23	Traditional	107

Supporting documents actually acquired

Go beyond the database row

Read the source context, then compare the evidence with your design. Topic locations below are text matches, including possible limitations or negative statements; they are not a mandatory test list.

K251722 · official summary PDF ↗

Term mention: Sterilization · PDF page 6 Term occurrence only; read the original passage, including limitations and negation.
Term mention: Performance testing · PDF page 11 Term occurrence only; read the original passage, including limitations and negation.
Term mention: Biocompatibility · PDF page 11 Term occurrence only; read the original passage, including limitations and negation.

K253033 · official summary PDF ↗

Term mention: Shelf life · PDF page 6 Term occurrence only; read the original passage, including limitations and negation.
Term mention: Biocompatibility · PDF page 8 Term occurrence only; read the original passage, including limitations and negation.
Term mention: Sterilization · PDF page 8 Term occurrence only; read the original passage, including limitations and negation.
Term mention: Performance testing · PDF page 9 Term occurrence only; read the original passage, including limitations and negation.

K250059 · official summary PDF ↗

Term mention: Performance testing · PDF page 7 Term occurrence only; read the original passage, including limitations and negation.
Term mention: Biocompatibility · PDF page 7 Term occurrence only; read the original passage, including limitations and negation.
Term mention: Sterilization · PDF page 8 Term occurrence only; read the original passage, including limitations and negation.

The documents are a bounded sample of acquired summaries, not complete evidence coverage of the cohort.

Recorded classification context

Known context: US. Match the intended use and design with the recorded category before treating it as applicable.

Source fact	Recorded value
FDA product code	ONB [1]
Generic device category	Closed Antineoplastic And Hazardous Drug Reconstitution And Transfer System [1]
Recorded scope	Reconstitute and transfer antineoplastic and other hazardous drugs in healthcare setting indicated to reduce exposure of healthcare personnel to chemotherapy agents in healthcare setting. [1]
Recorded class	2 [1]
Regulation	880.5440 [1]
Medical specialty	General Hospital [1]

Build a comparison that explains the differences

Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.

Which specific part of the recorded scope fits or differs?
Put your proposed label and design beside the quoted definition. Record matching facts, differences and missing facts separately; naming the category alone cannot resolve scope.
Useful evidence: Proposed indication/design and a definition-to-product comparison with source locators.
Have the cited section and its limitations been reviewed?
Record the applicable paragraph, conditions and cross-referenced limitations after specialist review. Keep a claimed exemption separate from actual establishment, listing and quality-system responsibilities.
Useful evidence: Dated classification/route rationale and the current provisions relied on, with unresolved conditions.
Compare your intended use with a named decision
Choose a named record above. Put your proposed claim beside its actual indications-for-use statement. Record different patients, users, anatomy, settings and output claims; do not treat a shared code as proof of equivalence.
Useful evidence: Your draft indications for use + the selected official summary and its exact page.
Explain the technology and evidence differences
For each comparison, record the different materials, hardware, software functions and operating conditions. Link each difference to existing evidence or an unresolved evaluation task.
Useful evidence: A three-column matrix: comparator fact / your design fact / evidence or unresolved gap.
Make the estimate comparable
Use the 2021–2025 cohort, and compare the recorded submission type before discussing calendar elapsed time. Separate your own preparation work from the recorded receipt-to-decision period.
Useful evidence: Chosen K numbers, submission types, dates and your own document/test readiness.

Work packages and dependencies

Conditional: FDA 510(k) Submission Services — Review the supplied facts and evidence gaps before confirming the service scope.
Optional: Find FDA US Agent Services | Compare & Get Quotes — Include only if your product, actor and delivery needs justify this additional scope. Confirm the responsibility and evidence handoff with the coordinating specialist.
Optional: FDA QMSR Transition & Inspection Readiness (ISO 13485 Alignment) — Include only if your product, actor and delivery needs justify this additional scope. Confirm the responsibility and evidence handoff with the coordinating specialist.

What needs to happen first

FDA 510(k) Submission Services → Find FDA US Agent Services | Compare & Get Quotes: Confirm the main product/actor scope and evidence gaps before deciding whether to commission this additional service.
FDA 510(k) Submission Services → FDA QMSR Transition & Inspection Readiness (ISO 13485 Alignment): Confirm the main product/actor scope and evidence gaps before deciding whether to commission this additional service.

Questions for providers

Which of the named ONB decisions are actually comparable to our proposed indications and technology, and which would you exclude?
Which evidence differences prevent us from using the comparison yet, and what deliverable resolves each one?
Does your schedule separate submission preparation, testing, FDA interactions and customer response time? What assumptions change it?

Sources and data dates

Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.